Relevance of serum angiogenic cytokines in adult patients with dermatomyositis

Table 3 Spearman’s correlation between angiogenic cytokines and diferent disease parameters

	ANG		ANGPT-1		FGF-1		FGF-2		VEGF		PDGF-AA		PDGF-BB
	rho	P	rho	P	rho	P	rho	P	rho	P	rho	P	rho	P
Current age			0.289	0.018							0.399	0.018
Age at disease onset			0.401	0.005	0.295	0.042					0.416	0.003
Disease duration			−0.448	0.001	−0.394	0.006					−0.326	0.024	−0.411	0.004
Body mass index									0.317	0.028
Facial rash	0.387	0.021			0.367	0.010
“V-neck” sign					0.338	0.019
“Shawl” sign			0.355	0.013	0.343	0.017
Pulmonary involvement	0.435	0.009
Patient VAS	0.410	0.014	0.326	0.024	0.351	0.014	−0.364	0.012
Physician VAS	0.476	0.004	0.387	0.007	0.341	0.018	−0.385	0.007			0.324	0.025
MMT-8			−0.470	0.001			−0.413	0.004			−0.457	0.001	−0.382	0.008
HAQ			0.400	0.005							0.338	0.019
Creatine phosphokinase			0.315	0.035
Aldolase			0.537	< 0.001	0.397	0.009	−0.344	0.028			0.469	0.002	0.478	0.002
Lactic dehydrogenase					0.339	0.023
Aspartate aminotransferase					0.429	0.004	−0.398	0.008			0.363	0.016	0.324	0.034
Alanine aminotransferase					0.379	0.010
Cyclosporin			−0.309	0.032
Prednisone (current use)			0.463	0.001	0.342	0.017					0.478	0.001	0.510	< 0.001
Prednisone (cumulative^a)			−0.390	0.006	−0.399	0.005	0.301	0.040			−0.315	0.029
ANG	1.000		0.366	0.001	0.512	< 0.001	−0.594	< 0.001			0.408	0.004
ANGPT-1	0.360	0.034	1.000		0.502	< 0.001	−0.453	0.001			0.820	< 0.001	0.725	< 0.001
FGF-1	0.344	0.034	0.502	< 0.001	1.000		−0.376	0.009			0.437	0.002
FGF-2			−0.543	0.001	−0.376	0.009	1.000				−0.459	0.001	−0.391	0.007
VEGF									1.000
PDGF-AA			0.820	< 0.001	0.437	0.002	−0.459	0.001			1.000		0.720	< 0.001
PDGF-BB			0.725	< 0.001			−0.391	0.007			0.720	< 0.001		1.000

ANG angiogenin, ANGPT-1 angiopoietin-1, FGF fibroblast growth factor, HAQ Health Assessment Questionnaire, MMT Muscle Manual Testing, P P value, PDGF platelet-derived growth factor-AA and BB; Rho: Spearmen’s correlation, VAS visual analogue scores, VEGF vascular endothelial growth factor
^aSince the disease onset symptoms

ISSN: 2523-3106